This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Factor XIII (fibrin stabilising factor) deficiency제13인자[피브린안정화]의 결핍 (제십삼인자피브린안정화인자결핍증)

Contents and key points
ItemDetails
A. Classification codesICD-10: D68.2 | Special Copayment Reduction: V009 (rare disease)
B. SynonymsFibrin stabilising factor deficiency, F13 deficiency, Laki-Lorand factor deficiency, factor XIII deficiency
C. Adult onsetVery low — mostly discovered early through umbilical cord bleeding in the neonatal period or intracranial hemorrhage in infancy; mild deficiency may be discovered through delayed bleeding after surgery in adulthood.
1. HistoryFirst description by Laki and Lorand in 1960. Origin of the name 'Laki-Lorand factor'. Identification of the last enzyme factor of the coagulation cascade.
2. CausesF13A1 gene (6p24.3) or F13B gene (1q31.3) variants; autosomal recessive; FXIII-A deficiency accounts for almost all cases.
3. GeneticsA2B2 heterotetramer structure; F13A1 (6p24.3)·F13B (1q31.3); high frequency in consanguineous populations (Iran, India, etc.).
4. EpidemiologyPrevalence of severe deficiency about 1 in 1–2 million; estimated at around 1,000 people worldwide; higher in consanguineous populations.
5. PathophysiologyFXIII → FXIIIa (activated by thrombin·Ca²⁺) → isopeptide cross-linking between fibrin monomers → formation of a stabilized fibrin clot; in FXIII deficiency, unstable clots form and are vulnerable to fibrinolysis.
6. SymptomsNeonatal umbilical cord bleeding (most characteristic), intracranial hemorrhage, joint and muscle bleeding, delayed postoperative bleeding, impaired wound healing, recurrent miscarriage.
7. SignsPT·APTT·TT·platelets all normal — 'a dangerous bleeding disorder with normal coagulation tests'; positive urea clot lysis test; FXIII:A activity measurement.
8. ScreeningNeonatal umbilical cord bleeding·intracranial hemorrhage → suspect FXIII after normal coagulation tests; family history; screening of consanguineous families; women with recurrent miscarriage.
9. DiagnosisUrea lysis test (classic) → quantitative FXIII:A activity (ELISA/chromogenic) → FXIII:A antigen and FXIII:B antigen → F13A1·F13B gene analysis.
10. TreatmentRecombinant FXIII-A (Tretten®), plasma-derived FXIII concentrates (Fibrogammin®/Corifact®); long-term prophylaxis possible (every 2–4 weeks); FFP·cryoprecipitate as alternatives.
11. PrognosisVery high risk of intracranial hemorrhage without treatment (lifetime risk about 25–30%); normal life possible with prophylaxis; life expectancy depends greatly on whether treatment is given.
12. PreventionRegular long-term prophylaxis; diagnosis and start of prophylaxis in the neonatal period; genetic counseling; early recognition of signs of intracranial hemorrhage; pregnancy management.
13. ReferencesFirst description by Laki K & Lorand L in 1948 and 11 or more other key references.

1. History

First discovery of fibrin stabilizing factor: Laki and Lorand

The history of coagulation factor XIII (FXIII, fibrin stabilizing factor) deficiency is closely intertwined with the history of basic coagulation research that uncovered the final step of fibrin clot formation. In 1948, the Hungarian-born biochemists Kálmán Laki and Loránd Lóránd (later active under the name Julius Lorand) discovered that something more than the simple polymerization of fibrinogen into fibrin occurs when a fibrin clot forms. They demonstrated biochemically that a type of covalent bond different from disulfide (-S-S-) bonds (later identified as the isopeptide bond) must form between fibrin monomers for the fibrin clot to be strongly stabilized. It was also established that the enzyme catalyzing this reaction exists in plasma as an inactive precursor (zymogen) and is activated by thrombin and calcium. Named after them, this factor came to be called Laki-Lorand factor (LLF) and was later standardized in the international nomenclature as coagulation factor XIII (Factor XIII).

First clinical description of FXIII deficiency: Duckert and Lorand

FXIII deficiency as a clinical disease was first described in 1960 by Franz Duckert and colleagues. They found that in a patient with a severe bleeding tendency, the clot dissolved in urea solution even though all existing coagulation tests (PT, APTT, etc.) were normal, and explained this as a deficiency of fibrin stabilizing factor. This discovery shocked the coagulation medicine community at the time. That a patient showed serious bleeding even though all standard coagulation tests were normal meant that the existing testing system did not evaluate the final step of the coagulation cascade—stabilization of the fibrin clot—at all. This clinical discovery established the key characteristic of the disease, that FXIII deficiency is 'a dangerous bleeding disorder with normal coagulation tests'. Subsequently, the 'urea clot solubility test' became established as the classic screening test for FXIII deficiency.

Elucidation of the molecular structure of FXIII: the A2B2 heterotetramer

During the 1970s–80s, the molecular structure of FXIII was gradually revealed. FXIII circulating in plasma was shown to be a heterotetramer (A2B2) composed of two types of subunits. The A subunit (FXIII-A, 83 kDa) is the catalytic unit with actual enzymatic activity (transglutaminase activity), and the B subunit (FXIII-B, 75 kDa) acts as a carrier protein that stabilizes the A subunit and facilitates its extracellular secretion. Platelets separately contain the FXIII-A homodimer (A2), which is released upon platelet activation and contributes to platelet-endothelial interaction and fibrin clot stabilization. When thrombin cleaves the activation peptide of FXIII-A and the B subunit then dissociates under the action of Ca²⁺, active FXIIIa is generated. FXIIIa forms isopeptide bonds at the Gln399-Lys406 linkage of the fibrin γ chain (γ-γ cross-link) and at several sites on the α chain, reinforcing the fibrin network three-dimensionally.

The dawn of the recombinant therapy era and the present

Until the end of the 20th century, treatment of FXIII deficiency relied on fresh frozen plasma (FFP), cryoprecipitate and plasma-derived FXIII concentrate (Fibrogammin®, CSL Behring). In the 2010s, recombinant FXIII (Tretten®, Novo Nordisk), composed of recombinant FXIII-A subunits, was developed and approved by the FDA (2013) and EMA (2012). This was the first recombinant therapy for congenital FXIII deficiency due to A subunit deficiency, making periodic prophylactic administration possible. With the introduction of long-term prophylaxis, the risk of intracranial hemorrhage in patients with FXIII deficiency has decreased markedly and quality of life has improved. Current challenges in FXIII deficiency research include developing treatments for B subunit deficiency, optimal management of clinical problems other than bleeding (impaired wound healing, recurrent miscarriage) and strategies to prevent inhibitor development.


2. Causes

F13A1 and F13B gene variants

FXIII deficiency is caused by variants in one of two separate genes. FXIII-A deficiency due to variants in the F13A1 gene (short arm of chromosome 6, 6p24.3), which encodes the A subunit of plasma FXIII, accounts for about 95–97% of all FXIII deficiency. FXIII-B deficiency due to variants in the F13B gene (long arm of chromosome 1, 1q31.3), which encodes the B subunit, is rare but shows a distinct clinical phenotype. Both genes follow autosomal recessive inheritance, and complete deficiency is expressed only when there are pathogenic variants on both alleles. The types of F13A1 gene variants are diverse, including missense, nonsense, splicing variants and insertions/deletions, and specific founder variants have been reported at high frequency in Middle Eastern (Iran, Iraq, Lebanon) and South Asian (India, Pakistan) populations.

Clinical differences between A subunit deficiency and B subunit deficiency

FXIII-A deficiency and FXIII-B deficiency differ in molecular mechanism and clinical phenotype. In FXIII-A deficiency, the enzymatically active unit itself is absent, so fibrin cross-linking does not occur at all, which leads directly to a severe bleeding phenotype. In FXIII-B deficiency, because the B subunit acts as the carrier protein for the A subunit, without the B subunit the A subunit is rapidly cleared from plasma. Thus FXIII-B deficiency also ultimately leads to reduced plasma FXIII activity, but there are reports that the intraplatelet FXIII-A2 homodimer remains normal, so the bleeding tendency may be milder than in FXIII-A deficiency. However, serious bleeding such as intracranial hemorrhage has also been reported in severe FXIII-B deficiency, so clinical attention is required.

Acquired FXIII deficiency and differentiation

In addition to primary deficiency due to congenital F13 gene variants, FXIII activity can be reduced by various acquired causes. The main causes of acquired FXIII deficiency include autoimmune diseases (production of autoantibodies against FXIII, particularly drug-induced autoantibodies such as with isoniazid and phenytoin), hematologic malignancies (leukemia, lymphoma), liver disease (reduced FXIII synthesis), inflammatory bowel disease (especially Crohn disease—increased FXIII consumption), massive bleeding or massive transfusion after surgery (FXIII reduction due to dilution and consumption) and postpartum uterine atony (reduced uterine contraction and FXIII consumption). Acquired FXIII deficiency presents as a bleeding tendency of sudden onset in adults, and unlike the congenital form, treatment of the underlying cause must be given concurrently. Genetic testing is the definitive tool for differentiating congenital from acquired forms.

Biological roles of FXIII beyond bleeding and their clinical relevance

In addition to fibrin cross-linking, FXIII has various biological substrates, which explains the diverse clinical features of FXIII deficiency. FXIII protects the fibrin clot from plasmin degradation through fibrin-α2-antiplasmin cross-linking. FXIII also strengthens cross-linking between platelet membrane GP IIb/IIIa and fibrin, increasing the stability of the platelet plug. In the wound healing process, it cross-links extracellular matrix proteins (fibronectin, collagen, vitronectin, etc.) within the fibrin matrix, forming a scaffold for tissue reconstruction. Delayed wound healing, reduced keloid formation and recurrent miscarriage in patients with FXIII deficiency result from impairment of this multifunctional role. FXIII is also involved in stabilizing the fibrin matrix during placental formation in pregnancy, which is why recurrent miscarriage increases in women with FXIII deficiency.


3. Genetics

Structure of the F13A1 gene and the transglutaminase domain

The F13A1 gene is located on the short arm of chromosome 6 at 6p24.3, with a total length of about 160 kb, and consists of 15 exons. The mature FXIII-A protein consists of 730 amino acids (molecular weight about 83 kDa). The protein structure consists of an N-terminal activation peptide (AP, Arg1-Gly37, including the thrombin cleavage site), a β-sandwich domain, the core transglutaminase (TG) domain (including the catalytic triad Cys314-His373-Asp396) and two barrel domains (barrel-1, barrel-2). The TG domain is the key site that catalyzes the formation of isopeptide (Nε-γ-glutamyl-lysine) bonds between the γ-carboxamide group of glutamine and the ε-amino group of lysine. These isopeptide bonds are much more resistant to acid, alkali and fibrinolytic enzymes than ordinary peptide bonds, which is why FXIII is called 'fibrin stabilizing factor'. To date, more than 100 pathogenic F13A1 variants have been reported, and various founder variants associated with the Val34Leu polymorphism have been identified in Middle Eastern populations such as in Iran and Iraq.

The F13B gene and Sushi domains

The F13B gene is located on the long arm of chromosome 1 at 1q31.3 and consists of 12 exons. The mature FXIII-B protein consists of 641 amino acids (molecular weight about 75 kDa) and is composed of 10 repeated Sushi domains (also called short consensus repeat, SCR, or CCP domains). The B subunit has no enzymatic activity and functions as a carrier and protective protein that envelops and stabilizes the A subunit dimer (A2). In plasma, FXIII circulates as an A2B2 heterotetramer, and this structure helps maintain the plasma half-life of the A subunit at about 9–10 days. In B subunit deficiency, the A subunit is rapidly degraded in plasma, and total FXIII activity is severely reduced. Conversely, when only the A subunit is deficient (the majority of all FXIII deficiency), the B subunit remains in excess in plasma.

Val34Leu polymorphism: association with cardiovascular risk

One of the clinically important polymorphisms studied in the F13A1 gene is the Val34Leu (p.Val34Leu) polymorphism resulting from the c.100G>T variant in exon 2. It is located just upstream of the thrombin cleavage site and alters the rate of FXIII activation by thrombin. Studies conflict: some show that in Val34Leu carriers FXIII is activated faster and a denser fibrin network resistant to fibrinolysis is formed, while others show, conversely, that a more easily lysed clot composed of thinner fibrin fibers is formed. Epidemiologically, some studies suggest that the Val34Leu polymorphism may have a protective effect against myocardial infarction, but the conclusions are inconsistent and it is not reflected in clinical practice. This polymorphism itself does not cause FXIII deficiency and should be understood as distinct from the disease-causing pathogenic variants.

Genetic risk in consanguineous populations

FXIII deficiency is an autosomal recessive disease, and the risk of occurrence is markedly higher in populations where consanguineous marriage is common. This is related to the concentrated reports of severe FXIII deficiency in populations of Iran, Iraq, Lebanon, India, Pakistan, Turkey and elsewhere. In particular, in first-cousin marriage the probability that a child is a homozygous carrier is determined by the frequency of heterozygous parents and the coefficient of inbreeding, and the higher the carrier frequency in a particular population, the higher the likelihood that a child with complete deficiency is born from a consanguineous marriage. In genetic counseling, it is important to check whether both partners in a consanguineous family are FXIII deficiency carriers and to explain to carrier couples the possibility of prenatal diagnosis (F13A1·F13B gene analysis using amniocentesis or chorionic villus sampling).


4. General epidemiology

Prevalence: the rarest of the coagulation factor deficiencies

Congenital FXIII deficiency (severe, FXIII:C <5%) is one of the rarest of all coagulation factor deficiencies, with a worldwide prevalence estimated at about 1 in 1–2 million people. According to the World Federation of Hemophilia (WFH) 2023 Annual Global Survey, there are about 900–1,200 officially registered patients with FXIII deficiency worldwide, which reflects only a portion of actual patients. A considerable number of cases are presumed to be undiagnosed, and in highly consanguineous populations some cases of death in infancy are lost without diagnosis. Mild FXIII deficiency (FXIII:C 5–70%) is more common, but there are no accurate prevalence data. The male-to-female ratio is 1:1 (autosomal recessive), and it can occur in any ethnic group but is markedly higher in consanguineous populations.

Geographic distribution and the influence of consanguineous marriage

The geographic distribution of patients with FXIII deficiency is disproportionately high in Middle Eastern, South Asian and Central Asian populations, where consanguineous marriage is relatively common. Particularly many cases have been reported in Iran, India and Pakistan, reflecting the concentration of recessive genetic diseases associated with consanguineous marriage customs along with improvements in the medical infrastructure of those countries. In Europe, North America and East Asia it occurs sporadically and rarely, and no specific founder variants have been reported. In Korea, FXIII deficiency is very rare and systematic data counting registered patients are lacking. Reported cases in Korea are a few published as case reports in academic journals, mainly presenting with umbilical cord bleeding in the neonatal period or intracranial hemorrhage in infancy.

Neonatal and infant presentation and age at diagnosis

The distribution of age at diagnosis of FXIII deficiency differs markedly from other coagulation factor deficiencies. Whereas severe hemophilia A·B is often discovered through neonatal circumcision or spontaneous joint bleeding in infancy, in FXIII deficiency cases first suspected through the very characteristic neonatal symptom of bleeding after separation of the umbilical cord account for about 80% or more of all patients. In normal newborns, the umbilical cord separates within 1–2 weeks after birth, and FXIII deficiency should be actively suspected when bleeding persists or recurs after the cord separates. The second most common presenting symptom is intracranial hemorrhage in infancy, which may occur spontaneously without trauma, so caution is needed because it can be mistaken for child abuse before FXIII deficiency is diagnosed. Mild deficiency is sometimes first discovered through delayed bleeding after surgery in adulthood.

Epidemiological significance and the need for rare disease registration

The extremely low prevalence of FXIII deficiency makes large randomized clinical trials impossible, so treatment evidence relies mainly on case reports, small cohorts and expert consensus. Internationally, efforts are under way to accumulate data through the World Federation of Hemophilia (WFH) Annual Global Survey, the European rare bleeding disorders registry system (RBDD registry) and individual national rare disease registries. In Korea, some patients are managed through rare disease Special Copayment Reduction (V009) registration, but there is not yet a national registry specific to FXIII deficiency. Building a national registry and long-term follow-up system is an urgent task for securing insurance coverage of treatments and standardizing treatment protocols.


5. Pathophysiology

The final enzyme of the coagulation cascade: the role of FXIII

Coagulation factor XIII (FXIII) is the enzyme responsible for the very last step of the coagulation cascade and determines the physical strength of the fibrin clot and its resistance to fibrinolysis. When thrombin cleaves fibrinopeptide A (FPA) and fibrinopeptide B (FPB) from the A alpha (Aα) and B beta (Bβ) chains of fibrinogen, respectively, fibrin monomers are generated, and they polymerize spontaneously via noncovalent hydrogen bonds to form soluble fibrin polymer. Up to this step a fibrin clot appears to form even without FXIII, but this initial fibrin network dissolves easily in 8M urea solution or 1% monochloroacetic acid. Only when FXIIIa forms isopeptide bonds between fibrin γ chains (γ-γ cross-links) and between α chains is the fibrin clot stabilized in the true sense.

Molecular mechanism of fibrin cross-linking by FXIIIa

FXIII activation occurs in two steps. In the first step, thrombin removes the activation peptide of FXIII-A (cleavage at Arg37-Gly38), inducing a conformational change, and in the second step Ca²⁺ dissociates the B subunit from the A subunit, exposing the catalytic active site. The FXIIIa thus generated (activated transglutaminase) forms isopeptide (Nε-γ-glutamyl-ε-lysyl) bonds between specific glutamine residues (Q-donor) and lysine residues (K-acceptor) of fibrin. The most important cross-linking site is the γ-γ bond between Gln399 (or Gln406) and Lys406 (or Lys396) of the fibrin γ chain, which covalently links the D fragments of fibrin dimers and reinforces the fibrin network two- and three-dimensionally. In addition, multiple cross-links between α chains, fibrin-α2-antiplasmin cross-links and fibrin-fibronectin cross-links further increase clot stability.

Clot instability and vulnerability to fibrinolysis in FXIII deficiency

In FXIII deficiency, fibrin formation itself through thrombin activation occurs, but because there is no cross-linking by FXIIIa, the fibrin clot that forms is mechanically fragile and easily broken down by fibrinolysis. Specifically, a fibrin clot without cross-links (1) is rapidly degraded by plasmin activated by endothelium-derived tPA and uPA, (2) has reduced fibrin binding of α2-antiplasmin, weakening the inhibition of plasmin, and (3) also has reduced clot retraction function compared with normal. For these reasons, in patients with FXIII deficiency bleeding at first appears to stop normally (because primary fibrin formation by thrombin occurs), but the clot dissolves within a few hours, and delayed rebleeding characteristically occurs. This is the mechanism by which rebleeding occurs within hours to days after umbilical cord separation.

Pathophysiology in wound healing and pregnancy

Understanding that the role of FXIII is not limited to fibrin stabilization but is also important in tissue repair and pregnancy is essential for explaining the diverse clinical features of FXIII deficiency. During wound healing, FXIIIa cross-links fibronectin, vitronectin and collagen within the fibrin matrix, forming an extracellular matrix scaffold for the migration and attachment of fibroblasts and vascular endothelial cells. In patients with FXIII deficiency, this scaffold formation is incomplete, so wound healing is delayed, and a clinical course of repeated delayed rebleeding and wound dehiscence is observed, especially at surgical sites with recurrent initial bleeding. During pregnancy, fibrin-fibronectin matrix formation by FXIIIa at the placental implantation site contributes to normal placental implantation and maintenance, so the risk of recurrent miscarriage and placental abruption increases in women with FXIII deficiency. In animal models, failure to maintain pregnancy has also been observed in FXIII-A knockout mice, supporting this hypothesis.


6. Symptoms

Neonatal umbilical cord bleeding: the most characteristic first symptom

The most characteristic and clinically important first symptom of FXIII deficiency is umbilical cord bleeding in the neonatal period. In normal newborns, the umbilical cord dries, shrinks and separates within 5–15 days after birth with only minimal bleeding. In newborns with FXIII deficiency, however, persistent and recurrent bleeding occurs from the umbilical stump within hours to days after cord separation. This bleeding shows a delayed pattern in which it at first appears to stop spontaneously and then rebleeds, and rebleeding recurs even with pressure using pads or gauze. When this characteristic umbilical cord bleeding occurs in the neonatal period and all standard coagulation tests (PT, APTT, TT, platelets) are normal, FXIII deficiency should be suspected first. If prompt FXIII testing and emergency treatment are not provided in this clinical situation, it can lead to serious intracranial hemorrhage.

Intracranial hemorrhage: a fatal complication

Intracranial hemorrhage (ICH) is the most lethal complication of FXIII deficiency, with a lifetime risk of about 25–30% in patients before diagnosis or with insufficient treatment. This risk is the highest of all coagulation factor deficiencies (compared with a lifetime ICH risk of about 2–5% in severe hemophilia A). Intracranial hemorrhage mostly occurs spontaneously without trauma or with delay after minor head contusion. The age of onset ranges from infancy to adulthood, but in patients who have not received prophylactic treatment it is concentrated in childhood. The clinical symptoms of intracranial hemorrhage vary with the location and size of the bleed, including headache, vomiting, seizures, altered consciousness and focal neurological deficits, and delayed diagnosis can lead to permanent neurological damage or death.

Other bleeding symptoms

In addition to umbilical cord bleeding and intracranial hemorrhage, patients with FXIII deficiency may experience bleeding symptoms at various sites. Spontaneous muscle hematomas and soft tissue hematomas are relatively common, and large hematomas of deep muscles (iliopsoas, gastrocnemius, etc.) may form. Intra-articular bleeding (hemarthrosis) can also occur, but it is less frequent than in hemophilia A·B and often not severe. Delayed postoperative bleeding shows a characteristic pattern in which hemostasis appears to be achieved within a few hours immediately after surgery and then rebleeding occurs after 24–48 hours. Recurrent epistaxis, gingival bleeding and gastrointestinal bleeding are also reported. In women, heavy menstrual bleeding and recurrent miscarriage are the main symptoms, and the risk of placental abruption during pregnancy is also high.

Impaired wound healing and recurrent miscarriage

Clinically important non-bleeding symptoms of FXIII deficiency besides bleeding include impaired wound healing and recurrent miscarriage. Impaired wound healing complicates the clinical course through postoperative wound dehiscence, secondary infection and the need for repeat surgery. This results from incomplete formation of the scaffold for tissue reconstruction due to lack of fibrin matrix-extracellular matrix cross-linking. Recurrent miscarriage occurs in early pregnancy (mainly the first trimester) and is presumed to be caused by failure to stabilize the fibrin matrix at the placental implantation site. Some guidelines recommend measuring FXIII:A activity in women with such recurrent miscarriage. There are clinical reports that appropriate FXIII replacement therapy during pregnancy enables prevention of miscarriage and successful delivery.


7. Signs

Normal coagulation screening tests: a diagnostic pitfall

The most clinically dangerous feature of FXIII deficiency is that all standard coagulation screening tests are normal. Prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen concentration, platelet count, bleeding time (BT or PFA-100) and platelet function tests are all within the normal range. This is because FXIII is responsible not for fibrin formation itself (steps 1–11 of the coagulation response) but for fibrin stabilization (the final cross-linking step). Standard coagulation tests measure the point at which fibrinogen is converted to fibrin (that is, visible clot formation) as the endpoint, so measurement is completed at the point when fibrin without cross-links has already formed. Therefore FXIII deficiency is described as 'a dangerous bleeding disorder with normal coagulation tests', and physicians unaware of this feature sometimes fail to find the cause of bleeding in newborns with umbilical cord bleeding or infants with intracranial hemorrhage and miss the diagnosis.

Urea clot solubility test

The urea clot solubility test (or urea clot lysis test), the classic screening test for FXIII deficiency, forms a fibrin clot from the patient's plasma with thrombin and calcium and then incubates the clot in 5M urea solution or 1% monochloroacetic acid at 37°C for 24 hours to observe whether it dissolves. In severe FXIII deficiency (<1–2% activity), the clot dissolves within minutes to hours, giving a positive result. This test has the limitation that when FXIII:A activity is about 2–3% or higher the clot does not dissolve and the result can be falsely negative, so mild or moderate FXIII deficiency can be missed. In addition, the sensitivity and specificity of the test may differ between laboratories and standardization is poor, so it is currently being replaced by quantitative FXIII:A activity measurement. However, its clinical value as a rapid and inexpensive screening tool in resource-limited settings is still recognized.

Quantitative FXIII:A activity measurement

The standard test for definitive diagnosis of FXIII deficiency is quantitative FXIII:A activity measurement. The most widely used method is the chromogenic substrate assay, which measures FXIII activity by quantifying the amine released when FXIIIa cross-links a peptide substrate. Other methods include ammonia release-based spectrophotometry and fluorescence methods. The normal range of FXIII:A activity varies by assay but is generally 70–140 IU/dL (or 70–140%); below 1–5 IU/dL is classified as severe deficiency, 5–30 IU/dL as moderate and 30–70 IU/dL as mild deficiency. Measurement of FXIII:A antigen (FXIII:A:Ag) and FXIII:B antigen (FXIII:B:Ag) is needed to differentiate the type of deficiency (A subunit deficiency vs. B subunit deficiency). In A deficiency, both FXIII:A:Ag and FXIII:B:Ag are often reduced (except when the B subunit is present in excess in plasma without the A subunit), whereas in B deficiency FXIII:B:Ag is reduced and FXIII:A:Ag is low or undetectable.

Thromboelastography and thrombin generation assays

Characteristic findings of FXIII deficiency may appear on whole-blood viscoelastic coagulation tests such as TEG (thromboelastography) or ROTEM (rotational thromboelastometry). In patients with FXIII deficiency, clot formation itself (Clot Formation Time, CFT) is normal, but maximum clot strength (Maximum Clot Firmness, MCF, or Maximum Amplitude, MA) may be reduced and fibrinolysis indices (LY30, LI60) may be increased. In particular, a marked reduction in MCF on FIBTEM (platelet-blocked conditions) is a clue to suspect fibrinogen- or FXIII-related abnormalities, including FXIII deficiency. In the thrombin generation assay (TGA), thrombin generation itself is normal, but subsequent assessment of fibrin stability is not directly measured in standard TGA protocols. Therefore TEG/ROTEM can provide screening clues for FXIII deficiency, but definitive diagnosis must be made by measuring FXIII:A activity.


8. Screening

FXIII screening in neonatal umbilical cord bleeding

The most important clinical situation for FXIII deficiency screening is when neonatal umbilical cord bleeding occurs and all standard coagulation tests are normal. This clinical pattern is a strong indicator of FXIII deficiency, and immediate FXIII:A testing and, if necessary, empirical treatment should be provided. When bleeding persists in a newborn with normal standard coagulation tests, the following differential diagnoses are considered: ① FXIII deficiency (specificity for umbilical cord bleeding), ② platelet dysfunction (normal platelet count but abnormal function), ③ thrombocytopenia (excluded after checking the platelet count), ④ fibrinogen dysfunction (dysfibrinogenemia, differentiated by TT and reptilase time), and ⑤ vitamin K deficiency (differentiated by PT prolongation). Of these, FXIII deficiency is the diagnosis most strongly associated with umbilical cord bleeding, so FXIII:A should be measured promptly with the combination of neonatal umbilical cord bleeding + normal coagulation tests.

Screening in infants with intracranial hemorrhage

In infants with intracranial hemorrhage without a clear history of trauma, coagulation abnormalities including FXIII deficiency must be evaluated as part of the process of differentiating various causes, including child abuse. Because FXIII deficiency cannot be excluded even when all standard coagulation tests are normal, FXIII:A activity measurement is essential in this situation. When FXIII deficiency is confirmed in an infant with intracranial hemorrhage, FXIII replacement therapy must be started immediately at the same time as treatment of the intracranial hemorrhage (deciding on surgery, managing intracranial pressure), followed by initiation of long-term prophylaxis. FXIII:A testing of the infant's parents and siblings to identify carriers in the family is also recommended.

FXIII screening in women with recurrent miscarriage

Some guidelines recommend measuring FXIII:A activity in women who have experienced unexplained recurrent miscarriage (habitual abortion, 3 or more consecutive or 2 or more pregnancy losses). Antiphospholipid antibody syndrome, chromosomal abnormalities, anatomical uterine abnormalities and endocrine disorders are well-known causes of recurrent miscarriage, but FXIII deficiency may also be included as a rare but correctable cause. When recurrent miscarriage due to FXIII deficiency is suspected, if FXIII:A activity is measured as low and other causes are excluded, FXIII replacement therapy during pregnancy can be tried to promote successful maintenance of pregnancy. There are reports that mild FXIII:A reduction (30–70 IU/dL) is associated with recurrent miscarriage, but sufficient evidence has not yet been established, so clinical judgment is needed.

Family history-based screening and testing of at-risk groups

As a rule, FXIII:A activity measurement is recommended for the parents and siblings of patients diagnosed with FXIII deficiency. The parents are mostly heterozygous carriers (FXIII:A activity about 40–70%), and they have no or very low clinical bleeding risk. If there is a homozygous carrier (complete deficiency) among the siblings, early detection allows prophylactic treatment to begin before umbilical cord bleeding in the neonatal period. In families where consanguineous marriage is common, many family members may be carriers or completely deficient, so broader family testing is needed. In addition, when a patient with FXIII deficiency plans pregnancy with a partner of reproductive age, it is recommended to perform FXIII:A testing on the partner as well, to confirm in advance whether both parents are carriers, and to provide genetic counseling.


9. Diagnosis

Diagnostic algorithm: from clinical suspicion to genetic analysis

The stepwise algorithm for definitive diagnosis of FXIII deficiency is as follows. Step 1: Recognize clinical situations of suspicion (neonatal umbilical cord bleeding, intracranial hemorrhage in infancy without trauma, delayed postoperative bleeding, recurrent miscarriage). Step 2: Confirm that standard coagulation tests (PT, APTT, TT, fibrinogen, platelets) are all normal (the key feature of FXIII deficiency). Step 3: Perform the urea clot solubility test; if the clot dissolves in urea solution, it is positive (FXIII deficiency strongly suspected). Step 4: Quantitatively measure FXIII:A activity (chromogenic method or ammonia release method) to determine severity. Step 5: Measure FXIII:A antigen and FXIII:B antigen to differentiate A subunit deficiency vs. B subunit deficiency. Step 6: For genetic confirmation, perform F13A1 (or F13B) gene analysis to identify the pathogenic variant. In family testing, FXIII:A activity measurement is performed first, and when a variant has been identified, carrier status is confirmed by gene-specific testing.

Technical details of the urea clot solubility test

The urea clot solubility test requires standardization and is performed as follows. Thrombin (1 NIH unit/mL or more) and calcium (25 mM CaCl₂) are added to the patient's citrated plasma and incubated at 37°C for 30 minutes to form a fibrin clot. The clot formed is incubated in 5M urea solution or 1% monochloroacetic acid at 37°C for 24 hours. If the clot has completely dissolved after 24 hours, the result is positive (FXIII deficiency suspected), and if the clot remains intact, it is negative. Normal plasma is tested together as a control to confirm the validity of the test. The sensitivity limit of this test is about 2–3% FXIII:A activity, so false negatives can occur in mild or moderate deficiency with residual activity above this level. To overcome this limitation, the quantitative chromogenic substrate assay is now established as the standard confirmatory test.

Principle and interpretation of the chromogenic FXIII:A activity assay

The most commonly used method for quantitative measurement of FXIII:A activity is the chromogenic assay. This method uses the reaction in which FXIIIa forms isopeptide bonds between a peptide glutamine substrate (Q-donor substrate) and an amine acceptor (such as biotin amine acting as a K-acceptor). The ammonia released in the reaction is quantified as a change in absorbance at 340 nm through NADH oxidation in a glutamate dehydrogenase-coupled reaction (GLDH-coupled reaction). The reference range varies somewhat by test kit but is generally 70–130 IU/dL. A point of caution in interpreting the results is that this test measures plasma FXIII and therefore does not reflect intraplatelet FXIII. In addition, acquired FXIII inhibitors (autoantibodies), when present, can interfere with the test. Whether heparin has been given must be checked before testing (heparin can affect FXIII activity measurement), and because FXIII activity can decline during plasma storage, frozen storage before analysis is necessary.

Clinical application of F13A1·F13B gene analysis

In patients with markedly reduced FXIII:A activity, F13A1 or F13B gene analysis is performed for definitive diagnosis and genetic counseling. Variants are identified by Sanger sequencing or an NGS-based rare bleeding disorder panel. The 15 exons and exon-intron boundaries of the F13A1 gene are analyzed in sequence, searching for missense, nonsense and frameshift variants and splicing variants in the coding region and regulatory variants in noncoding regions. After variant identification, pathogenicity classification is performed according to ACMG/AMP criteria. When common founder variants are known in particular regions (Iran, India, etc.), specific testing for those variants can be performed first to reduce testing cost and time. Genetic analysis results are used for genetic counseling, prenatal diagnosis and long-term follow-up planning.


10. Treatment

Recombinant FXIII-A (Tretten®)

Catridecacog alfa (Tretten®, Novo Nordisk), a recombinant therapy used to treat congenital FXIII-A subunit deficiency, is a recombinant FXIII-A subunit approved by the EMA in 2012 and the FDA in 2013. This product is a recombinant human FXIII-A subunit homodimer (A2) expressed in yeast (Saccharomyces cerevisiae); after administration it binds endogenous FXIII-B to form the A2B2 heterotetramer or exerts the function of FXIIIa on its own. The prophylactic dose is 35 IU/kg intravenously at 4-week intervals, and for acute bleeding 35 IU/kg is given as a single dose. The half-life is about 11 days, and a 4-week dosing interval can maintain a continuous prophylactic level (FXIII:A >5 IU/dL). Tretten® is indicated only for FXIII-A deficiency and does not apply to FXIII-B deficiency. As a recombinant product with no risk of viral transmission, it is an important alternative to plasma-derived products that carry a risk of viral infection.

Plasma-derived FXIII concentrates (Fibrogammin® / Corifact®)

The plasma-derived FXIII concentrates Fibrogammin® P (CSL Behring, Europe) and Corifact® (CSL Behring, USA) contain FXIII-A2B2 heterotetramer purified from human plasma and virus-inactivated. These products have the advantage of being usable for both FXIII-A deficiency and FXIII-B deficiency; 1,000–1,250 IU is given for bleeding treatment and 10–35 IU/kg at 2–4-week intervals for prophylaxis. Although they have undergone viral inactivation (SD treatment, wet heat treatment), a residual possibility of viral transmission theoretically exists compared with recombinant products. The half-life is about 9–10 days. Because these products are in the A2B2 heterotetramer form, they replace both FXIII-A and FXIII-B; they do not affect intraplatelet FXIII-A (A2 form) but effectively replace plasma FXIII.

Fresh frozen plasma and cryoprecipitate

In settings where specialized FXIII products are difficult to access, fresh frozen plasma (FFP) and cryoprecipitate can be used as alternatives. FFP contains FXIII at a concentration of about 1 IU/mL, and the therapeutic dose is calculated based on body weight. Cryoprecipitate contains FXIII, fibrinogen, FVIII, vWF and fibronectin, and its FXIII content per unit is higher than that of FFP, so FXIII can be replaced with a small volume. However, FFP and cryoprecipitate contain various plasma proteins and carry risks of allergic reactions and TRALI, and there is a risk of infection when viral inactivation is incomplete. Therefore, in developed countries they are currently used only to a limited extent for emergency treatment of acute bleeding when specialized products are unavailable, and they are not recommended for long-term prophylaxis.

Principles and monitoring of long-term prophylaxis

In patients with severe FXIII deficiency, long-term prophylaxis is strongly recommended to prevent intracranial hemorrhage. The target FXIII:A trough level is to be maintained at 5–10 IU/dL or higher, and maintaining this level is known to virtually eliminate the risk of intracranial hemorrhage. Tretten® is given at 35 IU/kg every 4 weeks and Fibrogammin® at 10–35 IU/kg every 2–4 weeks. FXIII:A trough levels are measured periodically before dosing to confirm that an appropriate prophylactic level is maintained. When special hemostatic stress such as surgery, trauma or childbirth is anticipated, it is recommended to give an additional dose to raise FXIII:A to 50–100 IU/dL or higher. Development of inhibitors (autoantibodies) is monitored periodically, and if inhibitors develop, immune tolerance induction therapy is considered. During pregnancy, intensive prophylaxis is needed with more frequent FXIII:A measurement and shortening of the dosing interval if necessary.


11. Prognosis

Prognosis before treatment: the risk of intracranial hemorrhage

The prognosis of untreated patients with severe FXIII deficiency is among the poorest of all coagulation factor deficiencies. In undiagnosed or untreated patients, the lifetime cumulative risk of intracranial hemorrhage is about 25–30%, much higher than the intracranial hemorrhage risk in untreated severe hemophilia A (about 2–5%). Intracranial hemorrhage is the main cause of death, and even survivors may be left with permanent neurological damage (cognitive impairment, motor paralysis, epilepsy, etc.). When neonatal umbilical cord bleeding is left untreated, there is also a risk of hypovolemic shock from excessive blood loss. When recurrent postoperative bleeding and impaired wound healing are combined, long-term morbidity also increases.

Prognosis after treatment: normal life possible

The prognosis of patients with severe FXIII deficiency who receive appropriate diagnosis and long-term prophylaxis has improved greatly. Early diagnosis and FXIII prophylaxis at 4-week intervals can lower the risk of intracranial hemorrhage to virtually zero, and normal physical activity and social and academic life are possible. Bleeding-related arthropathy and muscle complications can also be minimized with prophylactic treatment. The biggest clinical challenge of long-term prophylaxis is the development of inhibitors (alloantibodies), which can rarely occur in patients receiving repeated FXIII concentrate. When inhibitors develop, the effect of FXIII replacement therapy is markedly reduced, so in this case immunosuppressive therapy or bypassing therapy (rFVIIa, aPCC) should be considered. Life expectancy in patients who receive early diagnosis and prophylactic treatment does not differ greatly from the normal population.

Female patients and pregnancy prognosis

In women with FXIII deficiency, pregnancy and childbirth carry high risk without appropriate management. Recurrent miscarriage in early pregnancy, placental abruption during pregnancy and excessive bleeding during or after delivery can occur. However, there are clinical reports that prophylaxis maintaining FXIII:A at 30 IU/dL or higher during pregnancy enables successful maintenance of pregnancy and delivery. Around delivery, additional doses raising FXIII:A to 50–100 IU/dL are needed. In newborns, FXIII:A is measured in cord blood or perinatal blood for early diagnosis, and if deficiency is confirmed, prophylactic treatment is started from the neonatal period. With such active prenatal and perinatal management, successful pregnancy outcomes can be expected even in families with FXIII deficiency.

Long-term complications and follow-up management

In patients with FXIII deficiency receiving long-term prophylaxis, the main long-term complications besides inhibitor development include allergic reactions to treatment products, vascular access-related complications (venous damage from repeated intravenous injections), infections (central venous catheter-related) and thrombosis (a theoretical risk with excessive FXIII levels, especially with high-dose administration after surgery). Follow-up management includes periodic measurement of FXIII:A trough levels, inhibitor screening, recording of bleeding events, assessment of joint health and assessment of quality of life. In pediatric patients, monitoring of growth and development is also important. In terms of the long-term cost and burden of prophylaxis, patient education and home self-administration (home therapy) programs contribute to improved quality of life.


12. Prevention

Early diagnosis in the neonatal period and initiation of prophylactic treatment

The most effective prevention strategy for FXIII deficiency is immediate initiation of prophylactic treatment after early diagnosis in the neonatal period. In couples with a family history of FXIII deficiency, FXIII:A activity should be measured in cord blood or an early blood sample at birth to determine whether the newborn is deficient, and FXIII replacement therapy should be started as soon as severe deficiency is confirmed. This can prevent early complications such as umbilical cord bleeding and intracranial hemorrhage. Even in newborns without a family history, when umbilical cord bleeding occurs unexpectedly, FXIII:A measurement is performed immediately, and if deficiency is confirmed, treatment is started at once. When diagnosed in the neonatal period, starting prophylaxis within the first few weeks of life is the key strategy for preventing long-term neurological damage.

Continuation and monitoring of long-term prophylaxis

In patients with severe FXIII deficiency, continuous maintenance of long-term prophylaxis is the most important measure for preventing intracranial hemorrhage and other serious bleeding complications. If prophylaxis is stopped arbitrarily or the dosing interval is lengthened, FXIII:A falls below the critical level and the bleeding risk rises sharply. It is important to regularly remind patients and caregivers of the prophylaxis schedule and to educate them to systematically keep dosing records (date and time of dosing, dose, batch number). After starting and during prophylaxis, FXIII:A trough levels are measured every 3–6 months, and if the trough level is below the target (5–10 IU/dL), shortening the dosing interval or increasing the dose is considered. Before and after special hemostatic stress such as surgery, childbirth or trauma, it is important to raise FXIII:A sufficiently with additional doses.

Early recognition of intracranial hemorrhage and emergency response

From a preventive perspective, it is essential to educate patients with FXIII deficiency and their caregivers to recognize the early symptoms of intracranial hemorrhage (sudden headache, vomiting, seizures, altered consciousness, weakness of one arm or leg) and to obtain emergency care immediately. When intracranial hemorrhage is suspected, the patient should go to the emergency department without delay for head CT or MRI, and FXIII replacement therapy must be started immediately at the same time. Because it is important that emergency physicians or neurosurgeons who know about FXIII deficiency cooperate immediately, patients are advised to carry an emergency medical card or bracelet stating 'I have factor XIII deficiency and need immediate FXIII replacement therapy in an emergency of intracranial hemorrhage.' Even when prophylactic treatment is going well, the possibility of delayed bleeding after minor head contusion cannot be excluded, so neurological symptom changes are carefully observed for 48–72 hours after head trauma.

Genetic counseling and prenatal diagnosis

It is important to provide genetic counseling to the families of patients with FXIII deficiency. The counseling covers the autosomal recessive mode of inheritance, the probability of deficiency in children of carrier couples (25%), identification of carriers in the family through F13A1 or F13B variant testing, and the possibility of prenatal diagnosis for couples planning pregnancy. Prenatal diagnosis determines whether the fetus has complete deficiency by analyzing the fetal F13A1·F13B genes through amniocentesis (about 16–20 weeks) or chorionic villus sampling (about 11–13 weeks). Preimplantation genetic testing (PGT) is also technically possible and can offer the option of selecting and transferring embryos without FXIII deficiency through in vitro fertilization (IVF). This choice should be made according to the couple's values and wishes, and the role of the genetic counselor is to provide information on the various options neutrally.


13. References

  1. Laki K, Lorand L. On the solubility of fibrin clots. Science. 1948;108(2802):280.
  2. Duckert F, Jung E, Shmerling DH. A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thromb Diath Haemorrh. 1960;5:179-186.
  3. Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost. 2013;39(6):632-641.
  4. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol. 1999;107(3):468-484.
  5. Ivaskevicius V, Biswas A, Loreth R, et al. Mutations affecting disulphide bonds contribute to a large proportion of F13A1 gene defects causing inherited factor XIII A-subunit deficiency. Haemophilia. 2010;16(4):675-682.
  6. Nugent D. Factor XIII deficiency: clinical presentations and therapeutic options. Semin Thromb Hemost. 2011;37(3):253-255.
  7. Peyvandi F, Palla R, Menegatti M, et al. Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. J Thromb Haemost. 2012;10(4):615-621.
  8. Grimbergen J, Pulles AE, Danse E, et al. Recombinant factor XIII. Haemophilia. 2013;19 Suppl 4:1-6.
  9. Minami T, Shinozawa K. Factor XIII: structure, activation, and function. Semin Thromb Hemost. 2017;43(8):837-843.
  10. Muszbek L, Bereczky Z, Bagoly Z, et al. Factor XIII: a coagulation factor with multiple plasmatic and cellular functions. Physiol Rev. 2011;91(3):931-972.
  11. World Federation of Hemophilia. Guidelines for the Management of Rare Coagulation Disorders. Montreal: WFH; 2020.
  12. Bolton-Maggs PHB, Perry DJ, Chalmers EA, et al. The rare coagulation disorders: review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia. 2004;10(5):593-628.